Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:30 pm Purchase | 2026-03-31 | 13G | XILIO THERAPEUTICS INC XLO | BCLS II Equity Opportunities, LP | 664,021 9.990% | 216,897 (+48.51%) | Filing History |
| 2026-02-17 4:30 pm Purchase | 2025-12-31 | 13G | XILIO THERAPEUTICS INC XLO | BCLS II Equity Opportunities, LP | 447,124 8.500% | 120,923 (+37.07%) | Filing History |
| 2026-01-08 4:30 pm Sale | 2026-01-06 | 13D | MERSANA THERAPEUTICS INC N MRSN | BCLS II Equity Opportunities, LP | 0 0.000% | -198,720 (Position Closed) | Filing History |
| 2025-11-13 6:45 pm Unchanged | 2025-11-12 | 13D | MERSANA THERAPEUTICS INC N MRSN | BCLS II Equity Opportunities, LP | 198,720 4.000% | 0 (Unchanged) | Filing History |
| 2025-10-24 4:30 pm Purchase | 2025-10-17 | 13G | C4 THERAPEUTICS INC CCCC | BCLS II Equity Opportunities, LP | 6,060,000 6.250% | 6,060,000 (New Position) | Filing History |
| 2025-03-27 5:40 pm Purchase | 2025-03-25 | 13D | SAVARA INC SVRA | BCLS II Equity Opportunities, LP | 17,600,621 9.990% | 3,035,164 (+20.84%) | Filing History |
| 2024-11-15 4:45 pm Purchase | 2024-11-13 | 13D | MERSANA THERAPEUTICS INC MRSN | BCLS II Equity Opportunities, LP | 198,720 4.000% | 37,051 (+22.92%) | Filing History |
| 2024-11-14 5:44 pm Purchase | 2024-09-30 | 13G | XILIO THERAPEUTICS INC XLO | BCLS II Equity Opportunities, LP | 326,201 11.000% | 229,867 (+238.61%) | Filing History |
| 2024-11-14 5:24 pm Purchase | 2024-09-30 | 13G | SYROS PHARMACEUTICALS INC SYRS | BCLS II Equity Opportunities, LP | 2,750,151 11.000% | 343 (+0.01%) | Filing History |
| 2024-04-12 5:26 pm Purchase | 2024-04-10 | 13D | SAVARA INC SVRA | BCLS II Equity Opportunities, LP | 14,565,457 13.000% | 332,706 (+2.34%) | Filing History |
| 2024-03-29 5:16 pm Unchanged | 2024-03-27 | 13D | NUVALENT INC NUVL | BCLS II Equity Opportunities, LP | 2,400,630 4.100% | 0 (Unchanged) | Filing History |
| 2024-02-13 6:59 pm Purchase | 2023-12-31 | 13G | SYROS PHARMACEUTICALS INC SYRS | BCLS II Equity Opportunities, LP | 2,749,808 11.000% | 625,114 (+29.42%) | Filing History |
| 2023-10-20 4:30 pm Unchanged | 2023-10-19 | 13D | NUVALENT INC NUVL | BCLS II Equity Opportunities, LP | 2,400,630 4.200% | 0 (Unchanged) | Filing History |
| 2023-07-19 4:30 pm Purchase | 2023-07-17 | 13D | SAVARA INC SVRA | BCLS II Equity Opportunities, LP | 14,232,751 13.000% | 2,610,153 (+22.46%) | Filing History |
| 2023-02-14 06:15 am Sale | 2022-12-31 | 13G | SYROS PHARMACEUTICALS INC SYRS | BCLS II Equity Opportunities, LP | 2,124,694 11.000% | -4,139,726 (-66.08%) | Filing History |
| 2022-11-03 4:15 pm Unchanged | 2022-11-03 | 13D | NUVALENT INC NUVL | BCLS II Equity Opportunities, LP | 2,400,630 4.800% | 0 (Unchanged) | Filing History |
| 2022-05-11 5:26 pm Unchanged | 2022-05-09 | 13D | MERSANA THERAPEUTICS INC MRSN | BCLS II Equity Opportunities, LP | 161,669 4.200% | 0 (Unchanged) | Filing History |
| 2022-04-14 4:56 pm Purchase | 2022-04-13 | 13D | MERSANA THERAPEUTICS INC MRSN | BCLS II Equity Opportunities, LP | 161,669 4.800% | 29,892 (+22.68%) | Filing History |
| 2022-02-14 06:42 am Unchanged | 2021-12-31 | 13G | XILIO THERAPEUTICS INC XLO | BCLS II Equity Opportunities, LP | 96,334 4.900% | 0 (Unchanged) | Filing History |
| 2022-02-14 06:41 am Purchase | 2021-12-31 | 13G | SYROS PHARMACEUTICALS INC SYRS | BCLS II Equity Opportunities, LP | 626,442 11.000% | 47,938 (+8.29%) | Filing History |